Compare Stocks: ADMA, ACAD, ALLO, and TGTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$27.86 -3.7%	$27.16	$19.69 ▼ $30.96	$4.80B	0.86	1.66 million shs	1.85 million shs
ADMA ADMA Biologics	$9.58 +0.7%	$9.13	$7.21 ▼ $20.46	$2.15B	0.78	4.35 million shs	1.33 million shs
ALLO Allogene Therapeutics	$1.98	$1.99	$1.04 ▼ $4.46	$684.07M	0.47	7.94 million shs	4.42 million shs
TGTX TG Therapeutics	$56.71 -0.3%	$53.48	$26.76 ▼ $59.30	$8.68B	1.67	2.21 million shs	1.57 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+0.14%	-2.20%	+12.96%	+33.23%	+12.61%
ADMA ADMA Biologics	+1.93%	-1.25%	+8.81%	+19.40%	-44.71%
ALLO Allogene Therapeutics	-0.50%	-2.94%	+7.61%	-2.94%	+76.79%
TGTX TG Therapeutics	+1.44%	+3.40%	+23.24%	+40.29%	+91.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$27.86 -3.7%	$27.16	$19.69 ▼ $30.96	$4.80B	0.86	1.66 million shs	1.85 million shs
ADMA ADMA Biologics	$9.58 +0.7%	$9.13	$7.21 ▼ $20.46	$2.15B	0.78	4.35 million shs	1.33 million shs
ALLO Allogene Therapeutics	$1.98	$1.99	$1.04 ▼ $4.46	$684.07M	0.47	7.94 million shs	4.42 million shs
TGTX TG Therapeutics	$56.71 -0.3%	$53.48	$26.76 ▼ $59.30	$8.68B	1.67	2.21 million shs	1.57 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+0.14%	-2.20%	+12.96%	+33.23%	+12.61%
ADMA ADMA Biologics	+1.93%	-1.25%	+8.81%	+19.40%	-44.71%
ALLO Allogene Therapeutics	-0.50%	-2.94%	+7.61%	-2.94%	+76.79%
TGTX TG Therapeutics	+1.44%	+3.40%	+23.24%	+40.29%	+91.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.78	Moderate Buy	$34.36	23.33% Upside
ADMA ADMA Biologics	2.33	Hold	$18.67	94.85% Upside
ALLO Allogene Therapeutics	2.69	Moderate Buy	$8.30	319.19% Upside
TGTX TG Therapeutics	2.44	Hold	$63.00	11.09% Upside

Current Analyst Ratings Breakdown

Latest ADMA, ACAD, ALLO, and TGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	TGTX TG Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$78.00
8/26/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/25/2026	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$27.00 ➝ $28.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
8/17/2026	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $49.00
8/17/2026	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$6.00
8/12/2026	ACAD ACADIA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/12/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/12/2026	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $41.00
8/10/2026	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$27.00

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.07B	4.48	$0.86 per share	32.57	$7.58 per share	3.68
ADMA ADMA Biologics	$510.17M	4.21	$0.67 per share	14.26	$1.82 per share	5.26
ALLO Allogene Therapeutics	$20K	34,203.51	N/A	N/A	$1.26 per share	1.57
TGTX TG Therapeutics	$616.29M	14.09	$2.83 per share	20.02	$3.95 per share	14.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.22	12.55	28.43	21.54	33.42%	9.03%	6.79%	11/4/2026 (Estimated)
ADMA ADMA Biologics	$146.93M	$0.70	13.69	11.27	N/A	32.98%	40.17%	26.97%	11/4/2026 (Estimated)
ALLO Allogene Therapeutics	-$190.89M	-$0.67	N/A	N/A	N/A	N/A	-50.04%	-36.74%	11/5/2026 (Estimated)
TGTX TG Therapeutics	$447.18M	$2.74	20.70	21.40	2.40	55.22%	73.49%	34.14%	11/2/2026 (Estimated)

Latest ADMA, ACAD, ALLO, and TGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ALLO Allogene Therapeutics	-$0.1714	-$0.13	+$0.0414	-$0.13	$0.00 million	$4.64 million
8/5/2026	Q2 2026	ADMA ADMA Biologics	$0.1633	$0.16	-$0.0033	$0.16	$125.34 million	$124.40 million
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0682	$0.18	+$0.1119	$0.18	$296.55 million	$308.00 million
8/3/2026	Q2 2026	TGTX TG Therapeutics	$0.3057	$0.05	-$0.2557	$0.05	$229.77 million	$240.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.39	3.30
ADMA ADMA Biologics	0.49	6.97	3.81
ALLO Allogene Therapeutics	N/A	10.72	10.72
TGTX TG Therapeutics	1.23	4.27	3.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ADMA ADMA Biologics	75.68%
ALLO Allogene Therapeutics	83.63%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
ADMA ADMA Biologics	3.90%
ALLO Allogene Therapeutics	13.20%
TGTX TG Therapeutics	8.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	172.31 million	127.16 million	Optionable
ADMA ADMA Biologics	530	223.99 million	215.25 million	Optionable
ALLO Allogene Therapeutics	310	345.49 million	299.89 million	Optionable
TGTX TG Therapeutics	290	153.07 million	139.49 million	Optionable

ADMA, ACAD, ALLO, and TGTX Headlines

Recent News About These Companies

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

September 3 at 7:30 AM | globenewswire.com

Corient Private Wealth LP Purchases Shares of 39,081 TG Therapeutics, Inc. $TGTX

September 3 at 4:07 AM | marketbeat.com

HC Wainwright Reiterates "Buy" Rating for TG Therapeutics (NASDAQ:TGTX)

September 3 at 1:18 AM | americanbankingnews.com

IBD stock of the day, TG Therapeutics, eyes breakout after topping early buy point

September 2 at 5:50 PM | msn.com

TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?

September 2 at 12:31 PM | zacks.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Hold" from Analysts

September 2 at 4:13 AM | marketbeat.com

TGTX Stock Bounces Back as Analyst Downplays Threat from Novartis

September 1 at 7:28 PM | profitconfidential.comP

TGTX stock pares opening losses after analyst dismisses competition from Novartis

September 1 at 7:28 PM | msn.com

TG Therapeutics' (TGTX) Buy Rating Reaffirmed at HC Wainwright

September 1 at 1:23 PM | marketbeat.com

Jupiter Topco LLC Buys New Holdings in TG Therapeutics, Inc. $TGTX

September 1 at 4:55 AM | marketbeat.com

The Manufacturers Life Insurance Company Invests $4.27 Million in TG Therapeutics, Inc. $TGTX

September 1 at 4:55 AM | marketbeat.com

Legal & General Group Plc Invests $17.70 Million in TG Therapeutics, Inc. $TGTX

August 31 at 5:03 AM | marketbeat.com

Man Group plc Makes New Investment in TG Therapeutics, Inc. $TGTX

August 30, 2026 | marketbeat.com

Algert Global LLC Lowers Stock Position in TG Therapeutics, Inc. $TGTX

August 29, 2026 | marketbeat.com

Bank of New York Mellon Corp Takes $49.47 Million Position in TG Therapeutics, Inc. $TGTX

August 28, 2026 | marketbeat.com

PDT Partners LLC Acquires Shares of 41,585 TG Therapeutics, Inc. $TGTX

August 27, 2026 | marketbeat.com

TG Therapeutics Tests BRIUMVI in Schizophrenia: A New Angle for Long-Term Growth

August 26, 2026 | tipranks.com

TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)

August 26, 2026 | seekingalpha.com

Castleark Management LLC Buys Shares of 150,990 TG Therapeutics, Inc. $TGTX

August 26, 2026 | marketbeat.com

TGTX stock outperforms 95% of stocks. Here's why.

August 24, 2026 | msn.com

Great Lakes Advisors LLC Invests $1.11 Million in TG Therapeutics, Inc. $TGTX

August 23, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ADMA, ACAD, ALLO, and TGTX Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$27.86 -1.07 (-3.70%)

As of 04:00 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ADMA Biologics NASDAQ:ADMA

$9.58 +0.07 (+0.74%)

As of 04:00 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Allogene Therapeutics NASDAQ:ALLO

$1.98 0.00 (0.00%)

As of 04:00 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

TG Therapeutics NASDAQ:TGTX

$56.71 -0.19 (-0.33%)

As of 04:00 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADMA, ACAD, ALLO, and TGTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADMA, ACAD, ALLO, and TGTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADMA, ACAD, ALLO, and TGTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ADMA, ACAD, ALLO, and TGTX Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

ADMA Biologics NASDAQ:ADMA

Allogene Therapeutics NASDAQ:ALLO

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADMA, ACAD, ALLO, and TGTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADMA, ACAD, ALLO, and TGTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADMA, ACAD, ALLO, and TGTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ADMA, ACAD, ALLO, and TGTX Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

ADMA Biologics NASDAQ:ADMA

Allogene Therapeutics NASDAQ:ALLO

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools